Ann Intern MedJClub
In T2D, combined SGLT2i + GLP-1 RA vs. either alone does not reduce MACE or renal outcomes.
Annals of Internal Medicine · · Journal Article
Atri-Schuller, Montori + 1 more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
In people with type 2 diabetes, combined SGLT2 inhibitor plus GLP-1 receptor agonist therapy does not reduce MACE or renal outcomes versus either treatment alone.
- Why it matters: Clinicians need evidence on whether using SGLT2 inhibitors and GLP-1 receptor agonists together improves cardiovascular and kidney outcomes beyond monotherapy in type 2 diabetes.
- What they did: The study compared combined versus single-agent therapy for MACE and renal outcomes in a type 2 diabetes population, using a GIM/FP/GP framework.
- The result: The lack of reduction in both MACE and renal outcomes suggests the combination does not provide added benefit over either drug class alone for these endpoints in this setting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.